CD28 and congenital rubella syndrome: An initial trial of 16 patients with R/R myeloma treated with an anti-BCMA CAR T clone using a CD28 costimulatory domain showed an overall response (OR) rate of 81%; however, this construct induced high rates of toxicity, with 94% of patients developing CRS and 38% grade 3 or above (41).